Parenting and CAH - 21-hydroxylase Deficiency

Recruiting Observational Study
CAH - 21-Hydroxylase Deficiency
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Study type
Observational
Participants needed
200 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Congenital adrenal hyperplasia (CAH) is a genetic disease with autosomal recessive transmission, which is defined by a deficiency of one of the steroidogenesis enzymes. 21-hydroxylase deficiency (21OHD), related to mutations of the CYP21A2 gene, is involved in 90 to 95% of CAH cases. Depending on the severity of the mutations of this gene, there are severe forms known as "classic" (FC), with neona…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients aged 18 or over * Patients with HCS due to 21-hydroxylase deficiency, confirmed genetically * Patients who have been informed and do not object to participating in the research Exclusion Criteria: * Patients who do not speak French * Patients who are not affiliated …
Contacts

Anne BACHELOT

01 42 16 02 46

anne.bachelot@aphp.fr

CONTACT